Based on the fact that myostatin actions in the human body can be altered by other endocrine molecules such as the REST factor and that these alterations can influence metabolic regulatory measures such as the glycemic control of the diseased patients, myostatin can be a potential therapeutic target for the prevention of COVID-19-induced metabolic complications [137,138]. The gene discussed is MSTN; the disease is COVID-19.